KEY　WORD　分子高血圧

出版社： 先端医学社
著者：
発行日： 2002-05-10
分野： 臨床医学：一般  >  臨床医学一般
電子書籍版： 2002-05-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,170 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

学問の進歩は速く、その結果情報量だけでは等比級数的に増加している。錯綜するおびただしい情報のなかで、それぞれの分野におけるkey_wordと【がせねた】の区別こそは、新しい知識を日々活用する立場にある者にとって必須の事柄である。21世紀の医学研究は、ゲノムのステージからつぎのkey_word、プロテオームのステージへとパラダイムはシフトしている。このような時代背景にのっとり、key_word「高血圧」も時代にふさわしい「分子高血圧」へと衣替えし、求める側のニーズに応えようとしている。とはいえ、約130近い項目全てが遺伝子を含む分子生物学的項目ばかりではない。疫学からはじまる高血圧領域のkey_wordを選択し、up_dateの情報としてコンパクトに解説されている。（「序」より）

目次

  • KEY WORD　分子高血圧
    萩原俊男・島本和明・日和田邦男・藤田敏郎／編
    《311ページ》

    ―目　次―

    第１章　遺伝子／転写因子
    第２章　酵素／血管作動物質
    第３章　増殖因子／サイトカイン
    第４章　受容体／シグナル伝達
    第５章　病態生理／危険因子
    第６章　治療／疫学

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 遺伝子/ 転写因子

P.17 掲載の参考文献
1) Jeunemaitre X, Soubrier F, Kotelevtsev YV et al:Molecular basis of human hypertension:role of angiotensinogen. Cell 71:169-180, 1992
PubMed
2) Kim HS, Krege JH, Kluckman KD et al:Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92:2735-2739, 1995
PubMed
3) Ishikawa K, Baba S, Katsuya T et al:T+31C polymorphism of angiotensinogen gene and essential hypertension. Hypertension 37:281-285, 2001
PubMed
4) Sato N, Katsuya T, Nakagawa T et al:Nine polymorphisms of angiotensinogen gene in the susceptibility to essential hypertension. Life Sci 68:259-272, 2000
PubMed
5) Hunt SC, Cook NR, Oberman A et al:Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension:trials of hypertension prevention, phase II. Hypertension 32:393-401, 1998
PubMed
6) Iso H, Harada S, Shimamoto T et al:Angiotensinogen T174M and M235T variants, sodium intake and hypertension among non-drinking, lean Japanese men and women. J Hypertens 18:1197-1206, 2000
PubMed
7) Katsuya T, Koike G, Yee TW et al:Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 345:1600-1603, 1995
PubMed
8) Takami S, Imai Y, Katsuya T et al:Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 13:121-127, 2000
PubMed
P.19 掲載の参考文献
1) 檜垣實男, 荻原俊男:レニン-アンジオテンシン系および腎血管性高血圧. 内科学, 杉本恒明, 小俣政男編, 朝倉書店, 東京, 1999, pp.663-669
 
2) 檜垣實男, 荻原俊男:ACE遺伝子多型と疾患. 血圧 3:69-72, 1996
 
3) 勝谷友宏, 檜垣實男, 荻原俊男:アンジオテンシン変換酵素遺伝子. 内科 82:879-882, 1998
 
4) Cambien F, Costerousse O, Tirre L et al:Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 90:669-676, 1994
 
5) Samani NJ, Thompson JR, O'Toole L et al:A metaanalysis of the association of the deletion alele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712, 1996
 
P.21 掲載の参考文献
1) Ogryzko VV, Schiltz RL, Russanova V et al:The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959, 1996
PubMed
2) Petrij F, Giles RH, Dauwerse HG et al:Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376:348-351, 1995
PubMed
3) Tanaka Y, Naruse I, Maekawa T et al:Abnormal skeletal patterning in embryos lacking a single Cbp allele:apartial similarity with Rubinstein-Taybi syndrome. Proc Natl Acad Sci USA 94:100215-10220, 1997
 
P.23 掲載の参考文献
1) Lifton RP, Gharavi AG, Geller DS:Molecular mechanisms of human hypertension. Cell 104:545-556, 2001
PubMed
2) Deng AY:In search of hypertension genes in Dahl salt-sensitive rats. J Hypertens 16:1707-1718, 1998
PubMed
3) Cowley AW:Genetic and nongenetic determinants of salt sensitivity and blood pressure. Am J Clin Nutr 65 (suppl):587S-593S, 1997
 
P.25 掲載の参考文献
1) Resnick N, Collins T, Atkinson W et al:Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci USA 90:4591-4595, 1993
PubMed
2) Shyy JY, Lin MC, Han J et al:The cis-acting Phorbol ester "12-O-tetradecanoylphorbol 13-acetate"-responsive element is involved in shear stress-induced monocyte chemotactic protein l gene expression. Proc Natl Acad Sci USA 92:8069-8073, 1995
 
3) Lin MC, Almus-Jacks F, Chen HH et al:Shear stress induction of the tissue factor gene. J Clin Invest 99:737-744, 1997
 
4) Houston P, Dickson MC, Ludbrook V et al:Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thrombo Vasc Biol 19:281-289, 1999
 
P.27 掲載の参考文献
1) The International SNP Map Working Group:Amap of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933, 2001
 
2) Venter J, Adams M, Myers E et al:The sequence of the human genome. Science 291:1304-1351, 2001
 
3) Stephans J, Schneider J, Tanguay D et al:Haplotype variation and linkage disequilibrium in 313 human genes. Science 293:489-493, 2001
 
P.29 掲載の参考文献
1) Nakayama T, Soma M Izumi Y et al:Organization of the human prostacyclin synthase gene. Biochem Biophys Res Commun 221:803-806, 1996
PubMed
2) Nakayama T, Soma M, Rahmutla D et al:Nonsense mutation of the prostacyclin synthase gene in a family. Lancet 349:1887-1888, 1997
 
3) Nakayama T, Soma M, Rahmutla D et al:Association of 5' upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am J Hypertens 13:1263-1267, 2000
 
P.31 掲載の参考文献
1) Harvey RP:NK-2 homeobox genes and heart development. Dev Biol 178:203-216, 1996
PubMed
2) Schwartz RJ, Olson EN:Building the heart piece by piece:modularity of cis-elements regulating Nkx2-5 transcription. Development 126:4187-4192, 1999
PubMed
3) Nakamura M, Nishida W, Mori S et al:Transcriptional activation of beta-tropomyosin mediated by serum response facor and a novel Barx homologue, Barxlb, in smooth muscle cells. J Biol Chem 276:18313-18320, 2001
 
P.33 掲載の参考文献
1) 羽田明, 蒔田芳男:血管病におけるSNPs検索の意義. 血管医学 2:231-237, 2001
Medical*Online
2) http://lgb.unige.ch/arlequin/
PubMed
P.36 掲載の参考文献
1) International Humana Genome Sequencing Consortium:Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001
 
2) Tanaka T:Pharmacogenomics for Therapeutic Target Validation. In:First Pharmacogenomics and Pharmaco-genetics Forum, Ibaraki, 1999, pp.70-76
 
3) 田中利男, 林正晃, 西村有平ほか:薬理ゲノム科学と創薬. 21世紀の創薬科学, 辻本豪三, 田中利男編, 共立出版東京, 1998, pp.37-54
 
4) 田中利男, 田丸浩:臨床薬理ゲノミクス. 先端バイオ研究の進め方, 辻本豪三, 田中利男編, 羊土社, 2001, pp.110-185
 
5) Lazarou J, Pomeranz BH, Covey PN:Incidence of adverse drug reactions in hospitalized patients:a meta-analysis of prospective studies. JAMA 279:1200-1205, 1998
 
6) Suzuki H, Kanamaru K, Tsunoda H et al:Heme oxygenase-1gene induction as an intrinsic regulation against delayed cerebral vasospasm in rats. J Clin lnvest 104:59-66, 1999
 
7) Tanaka T, Nishimura U, Tsunoda H et al:Pharmaco-genomics and therapeutic target validation in cerebral vasospasm. J Cardiovasc Pharmacol 36 (suppl 2):S1-S4, 2000
 
8) Nishimura Y, Tanaka T:Calcium-dependent activation of NFIL3/E4BP4 gene expression by calcineurin/NAFT and CaM kinase signaling. J Biol Chem 276:19921-19928, 2001
 
9) 田中利男, 西村有平, 角田宏ほか:ゲノム創薬科学とファルマインフォマティクス. 蛋白質 核酸 酵素 45:805, 2000
 
P.39 掲載の参考文献
1) Shaywitz AJ, Greenberg ME:CREB:a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821-861, 1999
PubMed
2) Hai T, Hartman MG:The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors:activating transcription factor proteins and homeostasis. Gene 273:1-11, 2001
PubMed
P.41 掲載の参考文献
1) Shaulian E, Karin M:AP-1 in cell proliferation and survival Oncogene 20:2390-2400, 2001
PubMed
2) Vogt PK:Jun, the oncoprotein. Oncogene 20:265-2377, 2001
 
3) Li C, Xu Q:Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signal 7:435-445, 2000
PubMed
P.43 掲載の参考文献
1) Sato Y:Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct Funct 26:19-24, 2001
 
2) Teruyama K, Abe M, Nakano T et al:Neuropilin-1 is a downstream target of transcription factor Ets-1 in human umbilical vein endothelial cells. FEBS Lett 504:1-4, 2001
PubMed
P.45 掲載の参考文献
1) Black AR Azzikham-Clifford J:Regulation of E2F:a family of transcription factors involved in proliferation control Gene 237:281-302, 1999
 
2) Nevins JR:E2F:alink between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429, 1992
 
3) Mann M:E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts. Antisense & Nucleic Acid Drug Development 8:171-176, 1998
PubMed
4) Morishita R, Gibbons GH, Horiuchi M et al:Anovel molecular strategy using cis element"decoy"of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92:5855-5859, 1995
 
P.47 掲載の参考文献
1) Shivdasani RA, Orkin SH:The transcriptional control of hematopoiesis. Blood 87:4025-4039, 1996
PubMed
2) Molkentin JD:The zinc finger-containing transcription factors GATA-4,-5, and-6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 275:38949-38952, 2000
PubMed
P.49 掲載の参考文献
1) Kuro-o M, Matsumura Y, Aizawa H et al:Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51, 1997
PubMed
2) Saito Y, Yamagishi T, Nakamura T et al:Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248:324-329, 1998
PubMed
3) Aizawa H Saito Y, Nakamura T et al:Down regulation of the klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 249:865-871, 1998
PubMed
4) Saito Y, Nakamura T, Suga T et al :ln vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 276:767-772, 2000
 
P.51 掲載の参考文献
1) Akira S, Kishimoto T:NF-IL6 and NF-kappaB in cytokine gene regulation. Adr Immuuol 65:1-46, 1997
 
2) 改正恒康:転写因子C/EBPファミリーの生体内における機能. 蛋白質 核酸 酵素 45:1577-1584, 2000
 
3) Eickelberg O, Roth M, Mussmann R et al:Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-κB in primary human vascular smooth muscle alls. Circulation 99:2276-2282, 1999
 
P.53 掲載の参考文献
1) Chen F, Castranova V, Shi X:New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 159:387-397, 2001
PubMed
2) Collins T, Cybulsky MI:NF-kappaB:pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107:255-264, 2001
PubMed
3) Luft FC:Workshop:Mechanisms and cardiovascular damage in hypertension. Hypertensio 37[Part 2]:594-598, 2001
 

第2章 酵素/ 血管作動物質

P.57 掲載の参考文献
1) Furchgott RF, Zawadzki JV:The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376, 1980
PubMed
2) Griendling KK, Alexander RW:Endothelial control of the cardiovascular system:recent advances. FASEB J 10:283-292, 1996
PubMed
3) Miyamoto Y, Saito Y, Kajiyama N et al:Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32:3-8, 1998
PubMed
4) Takemoto M, Egashira K, Usui M et al:Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99:278-287, 1997
PubMed
5) Huang PL, Huang Z, Mashimo H et al:Hypertension in mice lacking the gene for endothelial nitric oxide synthase[see comments]. Nature 377:239-242, 1995
 
P.59 掲載の参考文献
1) Nakazono K, Watanabe N, Matsuno K et al:Does superoxide underline the pathogenesis of hypertension? Proc Natl Acad Sci USA 88:10045-10048, 1991
 
2) Vaziri ND, Wang XQ, Oveisi F et al:Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36:142-146, 2000
PubMed
3) Griendling KK, Minieri CA, Ollerenshaw JD et al:Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148, 1994
PubMed
4) Kerr S, Brosnan MJ, McIntyre M et al:Superoxideanion production is increased in a model of genetic hypertension:role of the endothelium. Hypertension 33:1353-1358, 1999
 
5) Ross R:Atherosclerosis-aninflammatory disease. N Engl Med 340:115-126, 1999
 
6) Stephens NG, Parsons A, Schofield PM et al:Randomised controlled trial of vitamin E in patients with coronary disease:Cambridge Heart Antioxidant Study (CHAOS). Lancet 347:781-786, 1996
PubMed
7) Virtamo J, Rapola JM, Ripatti S et al:Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fetal coronary heart desease. Arch lntern Med 158:668-675, 1998
 
8) Rapola JM, Virtamo J, Ripatti S et al:Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart 79:454-458, 1998
PubMed
P.61 掲載の参考文献
1) Hinson JP, Kapas S, Smith DM:Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21:138-167, 2000
PubMed
2) Juaneda C, Dumont Y, Quirion R:The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci 21:432-438, 2000
PubMed
3) 平田恭信:アドレノメデュリンの腎作用と腎疾患における役割. 循環器科 49:522-527, 2001
 
P.63 掲載の参考文献
1) Tsuji E, Tsuji Y, Misumi Y et al:Molecular cloning of a novel rat salt-tolerant protein by functional complementation in yeast. Biochem Biophys Res Commun 229:134-138, 1996
PubMed
2) Tsuji E, Tsuji Y, Sasaguri M et al:Function and expression of a novel rat salt-tolerant protein:evidence of a role in cellular sodium metabolism. J Am Soc Nephrol 9:1574-1580, 1998
PubMed
3) Gaxiola R de Larriona IF, Vilalba JM et al:Anovel and conserved salt-induced protein is an important determinant of salt tolerance in east. EMBOJ 11:3157-3164, 1992
 
4) Aspenstrom P:A Cdc42 target protein with homology to the non-kinase domain of FER has a protential role in regulating the actin cytoskeleton. Curr Biol 7:479-487, 1997
 
P.65 掲載の参考文献
1) Chung O, Unger T:Angiotensin II receptor blockade and end-organ protection. Am J Hypertens 12 (suppl):150S-156S, 1999
 
2) de Gasparo M, Catt KJ, Inagami T et al:International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472, 2000
PubMed
3) Dzau VJ:Theodore Cooper Lecture:Tissue angiotensin and pathobiology of vascular disease:a unifying hypothesis. Hypertension 37:1047-1052, 2001
 
P.67 掲載の参考文献
1) 名倉潤, 三木哲郎:早老症とテロメア. テロメア. テロメラーゼ, 山木戸道郎編, 日本医学館, 東京, 1999, pp.139-147
 
2) Aviv A:Hypothesis:pulse pressure and human longevity. Hypertension 37:1060-1066, 2001
PubMed
P.69 掲載の参考文献
1) Schnermann J, Traynor T, Pohl H et al:Vasoconstrictor response in thromboxane receptor knockout mice:tubuloglomerular feedback and ureteral obstruction. Acta Physiol Scand 168:201-207, 2000
PubMed
2) Ushikubi F, Sugimoto Y, Ichikawa A et al:Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. Jpn J Pharmacol 83:279-285, 2000
PubMed
3) Narumiya S, Sugimoto Y, Ushikubi F:Prostanoid receptors:structures, properties and functions. Physiol Rev 79:1193-1226, 1999
PubMed
P.71 掲載の参考文献
1) Goto A, Yamada K:Ouabain-like factor. Curr Opinion Nephrol Hypertens 7:189-196, 1998
 
2) Doris PA:Abnormalities of sodium pump function in hypertension and the role of cardiotonic steroids. Cell Mol Biol 47:391-401, 2001
PubMed
3) 後藤淳郎, 山田薫:内因性Naポンプ抑制因子-ジギタリス様物質. 医学のあゆみ 197:723-729, 2001
 
P.73 掲載の参考文献
1) Takamura Y, Simokawa H, Zhao H et al:Important role of endothelium-derived hyperpolarizing factor in shear stress-induced endothelium dependent relaxations in the rat mesenteric artery. J Cardiovasc Pharmacol 34:381-387, 1999
 
2) Cohen RA, Vanhoutte PM:Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 92:3337-3349, 1995
PubMed
3) Shimokawa H:Primary endothelial dysfunction:atherosclerosis. J Mol Cell Cardiol 31:23-37, 1999
PubMed
4) Quilly J, McGiff JC:Is EDHF an epoxyeicosatrienoic acid? Trends Pharmacol Sci 21:121-124, 2000
 
P.75 掲載の参考文献
1) 平田結喜緒:新しいホルモンと受容体研究の進歩「NO」. 最新内科学大系プログレス2, 中山書店, 東京, 1997, pp.50-54
 
2) Govers R, Rabelin K:Cellular regulation of endothelial nitric oxide synthase. Am J Phytiol 280:F193-F206, 2001
 
P.77 掲載の参考文献
1) Luscher TM, Boulanger CM, Dohi Y et al:Endothe lium-derived contracting factors. Hypertension 19:117-130, 1992
 
2) Vanhoutte PM:Endothelial dysfunction in hypertension. J Hypertens 14 (suppl):S83-S93, 1996
 
3) Shimokawa H:Endothelial dysfunction in hypertension. J Atheroscler Thromb 4:118-127, 1998
PubMed
4) Shimokawa H:Primary endothelial dysfunction. Atherosclerosis. J Mol Cell Cardiol 31:23-37, 1999
PubMed
P.79 掲載の参考文献
1) Urata H, Arakawa K:Angiotensin II-forming system in cardiovascular diseases. Heart Failure Reviews 3:119-124, 1998
 
2) Arakawa K, Urata H:Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 36:642-645, 2000
 
3) Urata H:Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease. Jraas 1 (suppl 2):S35-S37, 2000
 
P.81 掲載の参考文献
1) Narumiya S, FitzGerald GA:Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108:25-30, 2001
PubMed
2) Breyer MD, Breyer RM:G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63:579-605, 2001
PubMed
3) 中山智祥:PGI2合成酵素. 高血圧ナビゲイター, 荻原俊男, 猿田享男, 日和田邦男編, メディカルレビュー社, 大阪, 2000, pp.70-71
 
P.83 掲載の参考文献
1) Yu JX, Chao L, Chao J:Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem 269:18843-18848, 1994
PubMed
2) Yu JX, Chao L, Chao J:Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem 270:13483-13489, 1995
PubMed
3) Adachi M, Kitamura K, Miyoshi T et al:Activation of epithelial sodium channels by prostasin in Xenopus oocytes. J Am Soc Nephrol 12:1114-11121, 2001
PubMed
P.85 掲載の参考文献
1) Otterbein LE, Bach FH, Alam JS et al:Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6:422-428, 2000
 
2) Morita T, Kourembanas S:Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Invest 96:2676-2682, 1995
PubMed
3) Morita T, Perrella M, Lee ME et al:Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc Natl Acad Sci USA 92:1475-1479, 1995
PubMed
4) Zakhary R, Gaine SP, Dinerman GJ et al:Heme oxygenase 2:Endothelial and neuronal localization and role in endothelium-dependent relaxation. Proc Natl Acad Sci USA 93:795-798, 1996
 
5) Sabaawy HE, Zhang F, Nguyen X et al:Human heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats. Hypertension 38:210-215, 2001
PubMed
6) Imai T, Morita T, Shindo T et al:Vascular smooth muscle-directed overexpression of heme oxygenase-1 elevates blood pressure through attenuation of nitric oxide-induced vasodilation in mice. Circ Res 89:55-62, 2001
PubMed
7) Chiristou H, Morita T, Hsieh CM et al:Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in rat. Circ Res 86:1224-1229, 2000
 
8) Yet SF, Perrella MA, Layne MD et al:Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 96:2676-2682, 1995
 

第3章 増殖因子/ サイトカイン

P.89 掲載の参考文献
1) Maisonpierre PC, Suri C, Jones PF et al:Angiopoietin-2, anatural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997
 
2) Thurston G, Suri C, Smith K et al:Leakage-Resistant blood vessels in mice transgenically overexpressing Angiopoietin-1. Science 286:2511-2514, 1999
PubMed
3) Takakura N, Watanabe T, Suenobu S et al:A role for hematopoietic stem cells in promoting angiogenesis. Cell 102:199-209, 2000
PubMed
P.91 掲載の参考文献
1) Pennica D, King KL, Shaw KJ et al:Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 92:1142-1146, 1995
PubMed
2) Funamoto M, Hishinuma S, Fujio Y et al:Isolation and characterization of the murine cardiotrophin-1 gene:expression and norepinephrine-induced transcriptional activation. J Mol Cell Cardiol 32:1275-1284, 2000
PubMed
3) Okuno M, Nakagawa M, Shimada M et al:Expressional patterns of cytokines in a murine model of acute myocarditis:early expression of cardiotrophin-1. Lab Invest 80:433-440, 2000
 
4) Yamauchi-Takihara K Kishimoto T:Cytokines and their receptors in cardiovascular diseases-role of gp130 signalling pathway in cardiac myocyte growth and maintenance. Int J Exp Path 81:1-16, 2000
 
5) Tsutamoto T, Wada A, Maeda K et al:Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 38:1485-1490, 2001
PubMed
6) Wollert KC, Chien KR:Cardiotrophin 1 and the role of gp130-dependent signaling pathways in cardiac growth and development. J Mol Med 75:492-501, 1997
PubMed
P.93 掲載の参考文献
1) Nakano N, Morishita R, Moriguchi A et al:Negative regulation of local hepatocyte growth factor (HGF) expression by angiotensin II and transforming growth factor-beta in blood vessels:potential role of HGF in cardiovascular disease. Hypertension 32:444-451, 1998
PubMed
2) Nakano N, Moriguchi A, Morishita R et al:Role of Angiotensin II in the Regulation of a Novel Vascular Modulator, Hepatocyte Growth Factor (HGF), in Experimental Hypertensive Rats. Hypertension 30:1448-1454, 1997
PubMed
3) Nakamura Y, Morishita R, Nakamura S et al:A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 28:409-413, 1996
PubMed
4) Nakamura S, Moriguchi A, Morishita R et al:Anovel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun 242:238-243, 1998
 
P.95 掲載の参考文献
1) Carmeliet P, Moons L, Luttun A et al:Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575-583, 2001
PubMed
2) Celletti FL, Waugh JM Amabile PG et al:Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7:425-429, 2001
PubMed
3) Carmeliet P:VEGF gene therapy:stimulating angio-genesis or angioma-genesis? Nat Med 6:1102-1103, 2000
PubMed
P.97 掲載の参考文献
1) Hotamisligil GS, Shargill NS, Spiegelman BM:Adipose expression of tumor necrosis factor-α:Direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
 
2) Winkler G, Lakatos P, Salamon F et al:Elevated serum TNF-α level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med 16:207-211, 1999
 
3) Togashi N, Ura N, Higashiura K et al:The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18:1605-1610, 2000
 
4) Hotamisligil GS, Budavari A, Murray D et al:Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. J Clin lnvest 94:1543-1549, 1994
 
5) Long SD, Pekala PH:Lipid mediators of insulin resistance:ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 319:179-184, 1996
PubMed
6) Yerneni KK, Bai W, Khan BV et al:Hyperglycemia-induced activation of nucleartranscription factor kappa B in vascular smooth muscle cells. Diabetes 48:855-864, 1999
 
7) Samad F, Uysal KT, Wiesbrock SM et al:Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 96:6902-6907, 1999
 
8) Hotamisligil GS, Arner P, Atkinson RL et al:Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 46:451-455, 1997
PubMed
9) Fernandez-Real JM, Broch M, Ricart W et al:Plasma levels of the soluble fraction of tumornecrosis factor receptor 2 and insulin resistance. Diabetes 47:1757-1762, 1998
 
P.99 掲載の参考文献
1) de la Rosa A, Canessa CM, Fyfe GK et al:Structure and regulation of amlloride-sensitive sodium channels. Annu Rev Physiol 62:573-594, 2000
 
2) Benos DJ, Stanton BA:Functional domains within the degenerin/epithelial sodium channle (Deg/ENaC) superfamily of ion channels. J Physiol 520:631-644, 1999
PubMed
3) Corvol P, Persu A, Gimmenez-Roqueplo AP et al:Seven lessons from two candidate genes in human essential hypertension:angiotensinogen and epithelial sodium channel. Hypertension 33:1324-1331, 1999
 
4) Schild L, Lu Y, Gautschi I et al:Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. EMBO J 15:2381, 1996
PubMed
5) Chang H, Fujita T:Lack of mutations in epithelial sodium channel beta-subunit gene in human subjects with hypertension. J Hypertens 14:1417, 1996
PubMed
6) Persu A, Barby P, Bassilana F et al:Genetic analysis of the beta subunit of the epithelial Na+ channel in essential hypertension. Hypertension 32:129, 1998
 
P.101 掲載の参考文献
1) Luther SA, Cyster JG:Chemokines as regulators of T cell differentiation. Nature Immunology 2:102-107, 2001
PubMed
2) Reape TJ, Groot PHE:Chemokines and atherosclerosis. Atherosclerosis 147:213-225, 1999
 
P.103 掲載の参考文献
1) Topper JN:TGF-beta in the cardiovascular system:molecular mechanisms of a context-specific growth factor. Trends Cardiovasc Med 10:132-137, 2000
PubMed
2) 山下英俊:トランスフォーミング増殖因子β. Vascular Biology Navigator, メディカルレビュー社, 大阪, 2001, pp.102-103
 
P.104 掲載の参考文献
1) Steppan CM, Balley ST, Bhat S et al:The hormone resistin links obesity to diabetes. Nature 409:307-332, 2001
 
2) Steppan CM, Brown EJ, Wringht CM et al:A family of tissue-specific resistirlike molecules. Proc Natl Acad Sci USA 98:502-506, 2001
 
3) Banerjee RR, Lazar MA:Dimerization of resistin and resistin-like molecules is determined by a single cystein. J Biol Chem 276:25970-25973, 2001
PubMed
4) Way JM, Goerguen CZ, Tong Q et al:Adipose tissue resisin expression is severly suppressed in obesity and stimulated by peroxisome poliferator-activated receptor γ agonists. J Biol Chem 276:25651-25653, 2001
 
5) Nagaev I, Smith U:Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cels or skeletal muscle. Biochem Biophys Res Commun 285:561-564, 2001
 
6) Cao H, Hegele RA:Single nucleoide polymorphisms of the resistin gene. J Hum Genet 46:553-555, 2001
 
P.107 掲載の参考文献
1) Mikhail N Tuck ML:Obesity and hypertension. Prog Cardiovasc Dis 42:39-58, 1999
PubMed
2) Haynes WG:Interaction between leptin and sympathetic nervous system in hypertension. Curr Hypertens Rep 2:311-31, 2000
PubMed
3) Zhang R, Reisin E:Obesity-hypertension:the effects on cardiovascular and renal systems. Am J Hypertens 13:1308-1314, 2000
PubMed
P.109 掲載の参考文献
1) Kaibuchi K, Kuroda S, Amano M:Regulation of cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68:459-486, 1999
PubMed
2) Mukai Y, Shimokawa H, Matoba T et al:Involvement of Rho-kinase in hypertensive vascular disease:a novel therapeutic target in hypertension. FASEB J 10.1096/fj.00-0735je (Published online, 2001). FASEB J 15:1062-1064, 2001
 
3) Masumoto A, Hirooka Y, Shimokawa H et al:Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38:1307-1310, 2001
PubMed

第4章受容体/ シグナル伝達

P.113 掲載の参考文献
1) Cordero-Erausquin M, Marubio LM, Klink R et al:Nicotinic receptor function:new perspectives from knockout mice. Trends Pharmacol Sci 21:211-217, 2000
PubMed
2) Walch L, Brink C, Norel X:The muscarinic receptor subtypes in human blood vessels. Therapie 56:223-226, 2001
PubMed
3) 細谷幸雄:アセチルコリン受容体. Vascular Biologyナビゲーター, 丸山征郎, 安藤譲二, 佐藤靖史編, メディカルレビュー社, 大阪, 1997, pp.140-141
 
P.115 掲載の参考文献
1) Ishikawa Y, Homcy CJ:The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res 80:297-304, 1997
PubMed
2) Ishikawa Y:Diversity of adenylyl cyclases isoforms and their regulation in the heart. J Cardiovasc Pharmacol 34 (suppl):S3-S5, 1999
 
3) Chen Y, Cann MJ, Litvin TN et al:Soluble adenylyl cyclase as an evolutionally conserved bicarbonate sensor. Science 289:559-560, 2000
 
4) Wedel BJ, Garbers DL:New insights on the functions of the guanylyl cyclase receptors, FEBS Lett 410:29-33, 1997
PubMed
5) Koesling D:Studying the structure and regulation of soluble guanylyl cyclase. Methods 19:485-493, 1999
 
6) Hurley JH:The adenylyl and guanylyl cyclase superfamily. Curr Opin Struct Biol 8:770-777, 1998
PubMed
7) Onda T, Hashimoto Y, Nagai M et al Type-specific regulation of adenylyl cyclase:selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem 276:47785-47793, 2001
PubMed
P.117 掲載の参考文献
1) Kitamura K, Eto T:Adrenomedullin-physiological regulator of the cardiovascular system or biochemical curiosity? Curr Opin Nephrol Hypertens 6:80-87, 1997
 
2) Foord S M, Marshall F H:RAMPs:accsssory proteins for seven transmembrane domain receptors. Trends Pharmacot Sci 20:184-187, 1999
PubMed
3) Kuwasako K, Shimekake Y, Masuda M et al:Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem 275:29602-29609, 2000
PubMed
4) Sexton PM, Albiston A, Morfis M et al:Receptor activity modifying proteins. Cellular Signaling 13:73-83, 2001
PubMed
5) Hilairet S, Foord SM, Marshall FH et al:Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying Proteins. J Biol Chem 276:29575-29581, 2001
 
P.119 掲載の参考文献
1) Horiuchi M, Akishita M, Dzau VJ:Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33:613-621, 1999
PubMed
2) Horiuchi M, Lehtonen JY, Daviet L:Signaling Mechanism of the AT2 Angiotensin II Receptor:Crosstalk between ATI and AT2 Receptors in Cell Growth. Trends Endocrinol Metab 10:391-396, 1999
 
3) de Gasparo M, Catt KJ, Inagami T et al:International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472, 2000
PubMed
P.121 掲載の参考文献
1) Shears SB:The versatility of inositol phosphates as cellular signals. Biochim Biophys Acta 1436:49-67, 1998
PubMed
2) Berridge MJ:Inositol trisphosphate and calcium signalling Nature 361:315-324, 1993
PubMed
3) Huisamen B, Lochner A:Inositol polyphosphates and their binding proteins. Mol Cell Biochem 157:229-232, 1996
PubMed
P.123 掲載の参考文献
1) Arnqvist HJ, Bornfeldt KE, Chen Y et al:The insulin-like growth factor system in vascular smooth muscle:Interaction with insulin and growth factors. Metabolism 44 (suppl 4):S58-S66, 1995
 
2) Adams TE, Epa VC, Garrett TP et al:Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol life Sci 57:1050-1093, 2000
PubMed
3) Delafontaine P:Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 30:825-834, 1995
PubMed
4) Valentinis B, Baserga R:IGF-I receptor signalling in transformation and differentiation. Mol Pathol 54:133-137, 2001123
 
P.125 掲載の参考文献
1) Dinarello CA:Biologic basis for interleukin-1 in diease. Blood 87:2095-2147, 1996
 
2) Dinarello CA:Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Intern Rev Immunol 16:457-499, 1998
 
3) Watkins LR, Hansen MK, Nguyen KT et al:Dynamic regulation of the proinflammatory cytokine, interleukin-1β:molecular biology for non-molecular biologists. Life Sci 65:449-481, 1999
 
P.127 掲載の参考文献
1) Ikeda U, Ito T, Shimada K:Interleukin 6 and acute coronary syndrome. Clin Cardiol 24:701-704, 2001
PubMed
2) Ikeda U, Okawa F, Seino Y et al:Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 24:579-584, 1992
 
3) Ridker PM, Rifai N, Stampfer MJ et al:Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767-1772, 2000
PubMed
P.129 掲載の参考文献
1) Masaki T:Possible role of endothelin in endothelial regulation of vascular tone. Ann Rev Pharmacol Toxicol 35:235-255, 1995
 
2) Webb DJ, Monge JC, Rabelink TJ et al:Endothelin:new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 19:5-8, 1998
 
3) Kurihara H, Kurihara Y, Nagai R et al:Endothelin and neural crest development. Cell Mol Biol 45:639-651, 1999
PubMed
P.131 掲載の参考文献
1) 海老名俊明, 内野和顕, 梅村敏:βアドレナリン受容体遺伝子. 日本臨牀 58:546-549, 2000
Medical*Online
2) Kable JW, Murrin LC, Bylund DB:In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J Pharmacol Exp Ther 293:1-7, 2000
PubMed
P.133 掲載の参考文献
1) Anderson RG:The caveolae membrane system. Annu Rev Biochem 67:199-225, 1998
PubMed
2) Simons K, Toomre D:Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31-39, 2000
PubMed
P.135 掲載の参考文献
1) Karaki H, Ozaki H, Hori M et al:Calcium movements, distribution and functions in smooth muscle. Pharmacol Rev 49:157-230, 1997
PubMed
2) 唐木英明:Ca2+チャネルの分子生物学. Ca拮抗薬のすべて, 猿田享男ほか編, 先端医学社, 東京, 1995, pp.360-372
 
P.137 掲載の参考文献
1) Heldin CH:Structural and functional studies on platelet-derived growth factor. EMBO J 11:4251-4259, 1992
PubMed
2) Dzau VJ, Gibbons GH, Cooke Jp et al:Vascular biology and medicine in the 1990s:scope, concepts, patentials and prospectives. Circulation 87:705-719, 1993
 
3) Uutela M, Lauren J, Bergsten E et al:Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD) genes. Circulation 103:2242-2247, 2001
PubMed
P.139 掲載の参考文献
1) Hamill OP, Martinac B:Molecular basis of mechanotransduction in living cells. Physiol Rev 81:685-740, 2000
 
2) Hamil, OP, MacBride DWJr:The pharmacology of mechanogated membrane lon channels. Pharmacol Rev 48:231-252, 1996
 
3) 曽我部正博, 成瀬恵治, 嶽本和久:SAチャネルは細胞の機械センサーか? 蛋白質 核酸 酵素 41:2-13, 1996
 
P.141 掲載の参考文献
1) Galzie Z, Kinsella AR, Smith JA:Fibroblast growth factors and their receptors. Biochem Cell Biol 75:669-685, 1997
PubMed
2) Szebenyi G, Fallon JF:Fibroblast growth factors as multifunctional signaling factors. lnt Rev Cytol 185:45-106, 1999
 
3) 竹内郁登, 吉竹佳乃, 西川克三:線維芽細胞増殖因子 (FGF). Vascular Biology ナビゲーター, 丸山征郎, 安藤譲二, 佐藤靖史編, メディカルレビュー社, 大阪, 2001, pp.106-107
 
P.143 掲載の参考文献
1) Daniel PT, Wieder T, Sturm I et al:The kiss of death:promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022-1032, 2001
PubMed
2) Ashkenazi A, Dixit VM:Death receptors:Signaling and modulation. Science 281:1305-1308, 1998
PubMed
P.145 掲載の参考文献
1) Missale C, Nash R, Robinson SW et al:Dopamine receptors:from structure to function. Physiol Rev 78:189-225, 1998
 
2) Jose PA, Eisner GM, Felder RA:Renall dopamine and sodium homeostasis. Curr Hypertens Rep 2:174-183, 2000
 
3) Kunimi M, Seki G, Hara C et al:Dopamine inhibits renal Na+:HCO3-cotransporter in rabbits and normotensive rats but not in spontaneously hypertensive rats. Kidney Int 57:534-543, 2000
 
4) Kinoshita S, Sidhu A, Felder RA:Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat. J Clin Invest 84:1849-1856, 1989
PubMed
P.149 掲載の参考文献
1) Kangawa K, Matsuo H:Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 118:131-139, 1984
PubMed
2) deBold AJ, Borenstein HB, Veress AT et al:Arapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28:89-94, 1981
 
3) Nakao K, Itoh H, Saito Y et al:The natriuretic peptide family. Curr Opin Cardiol 5:4-11, 1996
 
P.151 掲載の参考文献
1) Yoshida H, Zhang JJ, Chao L et al:Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35:25-31, 2000
PubMed
2) Wolf WC, Yoshida H, Agata J et al:Human tissue kallikrein gene delivery attenuates hypertension, renal injury and cardiac remodeling in chronic renal failure. Kidney lnt 58:730-739, 2000
 
3) Agata J, Miao RQ, Yayama K et al:Bradykinin B1 receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 36:364-370, 2000
PubMed
P.153 掲載の参考文献
1) Narumiya S, FitzGerald GA:Genetic and pharmacological analysis of prostanoid receptor function. J Clin lnvest 108:25-30, 2001
 
2) Breyer MD, Breyer RM:G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63:579-605, 2001
PubMed
3) Breyer RM, Bagdassarian CK, Myers SA et al:Prostanoid receptors:subtype and signaling. Annu Rev Pharmacol Toxicol 41:661-690, 2001
PubMed
P.155 掲載の参考文献
1) Nishizuka Y:Studies and perspectives of protein kinase C. Science 223:305-312, 1986
 
2) Parekh DB, Ziegler W, Parker PJ:Multiple pathways control protein kinase C phosphorylation. EMBO J 19:496-503, 2000
 
3) Takuwa Y:Regulation of vascular smooth muscle contraction. The roles of Ca2+, protein kinase C and myosin light chain phosphatase:Jpn Heart J 37:793-813, 1996
PubMed
P.157 掲載の参考文献
1) Fruchart JC, Duriez P, Staels B:Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 3:245-257, 1999
PubMed
2) Bishop-Bailey D:Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129:823-834, 2000
PubMed
3) Lazar MA:Progress in cardiovascular biology:PPAR for the course. Nat Med 7:23-24, 2001
PubMed
4) Chinetti G, Lenstavel S, Bocher V et al:PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCAI pathway. Nat Med 7:53-58, 2001
 
P.159 掲載の参考文献
1) Rameh LE, Cantley LC:The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274:8347-8350, 1999
PubMed
2) 佐々木雄彦, 鈴木聡, 佐々木純子ほか:PI-3キナーゼとPIホスファターゼの免疫応答, 糖代謝, 腫瘍形成における役割. 蛋白質 核酸 酵素 46:1820-1829, 2001
 
3) 荻原健英, 浅野知一郎, 迫田秀之ほか:インスリンシグナル伝達機構とインスリン感受性増強薬. Pharma Medica 19:33-38, 2001
Medical*Online
P.162 掲載の参考文献
1) Singer WD, Brown HA, Sternweis PC:Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Annu Rev Biochem 66:475-509, 1997
PubMed
2) Rhee SG, Bae YS:Regulation of phosphoinositide specific phospholipase C isozymes. J Biol Chem 272:15045-15048, 1997
PubMed
3) 坂野喜子, 野澤義則:ホスホリパーゼC. 蛋白質 核酸 酵素 44:989-997, 1999
 
P.165 掲載の参考文献
1) Kita T:LOX-1, a possible clue to the missing link between hypertension and atherogenesis. Circ Res 84:1113-1115, 1999
 
2) Kuma N, Kita T:Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in athrogenesis. Curr Opin Lipidol 12:419-423, 2001
 
P.167 掲載の参考文献
1) Hofmann F, Ammendola A, Schlossmann J:Rising behind NO:cGMP-dependent protein kinases. J Cell Sci 113:1671-1676, 2000
PubMed
2) Pfeifer A, Ruth P, Dostmann W et al:Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 135:105-149, 1999
PubMed
P.169 掲載の参考文献
1) Siffert W, Rosskopf D, Siffert G et al:Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 18:45-49, 1998
 
2) Iiri T, Farfel Z, Bourne HR:G-protein diseases furnish a model for the turn-on switch. Nature 394:35-38, 1998
 
3) Penn RB, Pronin AN, Benovic JL:Regulation of G protein-coupled receptor kinase. Trends Cardiovasc Med 10:81-89, 200
 
4) Uehata M, Ishizaki T, Satoh H et al:Calcium sensitization of smooth muscle mediated by a Rho-associated potein kinase in hypertension. Nature 389:991-994, 1997
 
P.171 掲載の参考文献
1) Hirano T, Nakajima K, Hibi M:Signaling mechanisms through gp130:a model of the cytokine system. Clytokine Growth Factor Rev 8:241-252, 1997
 
2) Ihle JN:The stat family in cytokine signaling. Curr Opin Cell Biol 13:211-217, 2001
PubMed
3) Yamauchi-Takihara K, Kishimoto T:A novel role for STAT3 in cardiac remodeling. Trend Cardiovasc Med 10:298-303, 2000171
 
P.173 掲載の参考文献
1) Pearson G, Robinson F, Gibson TB et at:Mitogen-activated protein (MAP) kinase pathways:regulation and physiological functions. Endocr Rev 22:153-183, 2000
 
2) Li C, Xu Q:Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signal 12:435-445, 2000
PubMed

第5章 病態生理/ 危険因子

P.177 掲載の参考文献
1) Higashiura K, Ura N, Takada T et al:Alteration of muscle fiber composition linking to insulin resistance and hypertension in fructose-fed rats. Am J hypertens 12:596-602, 1999
PubMed
2) Hotamisligil GS, Budavari A, Murray D et al:Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. J Clin lnvest 94:1543-1549, 1994
 
3) Shimamoto K, Hirata A, Fukuoka M et al:lnsulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patirnts. Hypertension 23 (suppl 1):I-29-I-33, 1994
 
P.179 掲載の参考文献
1) Egashira K, Hirooka Y, Kai H et at:Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89:2519-2524, 1994
 
2) Anderson TJ, Meredith IT, Yeung AC et al:The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488-493, 1995
 
3) Mancini GB, Henry GC, Macaya C et al:Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94:258-265, 1996
PubMed
4) Minor RLJr, Myers PR, Guerra RJr et al:Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin lnvest 86:2109-2116, 1990
 
5) Berliner JA, Navab M, Fogelman AM et al:Athersclerosis:basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91:2488-2496, 1995
 
P.181 掲載の参考文献
1) Mulvany MJ, Baumbach GL, Aalkjaer C et al:Vascular remodeling. Hypertension 28:505-506, 1996
PubMed
2) Gibbons GH, Dzau VJ:The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438, 1994
PubMed
3) Glagov S, Weisenberg E, Zarins CK et al:Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371-1375, 1987
PubMed
4) Di Mario C, Gil R, Camenzind E et al:Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol 75:772-777, 1995
PubMed
5) Hoffmann R, Mintz GS, Popma JJ et al:Chronic arterial responses to stent implantation:a derial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. J Am Coll Cardiol 28:1134-1139, 1996
PubMed
6) Moroi M, Zhang L, Yasuda T et al:Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin lnvest 101:1225-1232, 1998
 
P.183 掲載の参考文献
1) Nakazono K, Watanabe N, Inoue M et al:Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88:10045-10048, 1991
PubMed
2) Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL:Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 36:957-964, 2000
 
3) Duffy SJ, Gokce N, Holbrook M et al:Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol 280:H528-H534, 2001
PubMed
P.185 掲載の参考文献
1) ACOG Practice Bulletin:Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins. Obstet Gynecol 98:177-185, 2001
 
2) Ferrer RL, Sibai BM, Mulrow CD et al:Management of mild chronic hypertension during pregnancy. Obstet Gynecol 96:849-860, 2000
PubMed
3) Dekker GA, Sibai BM:Etiology and pathogenesis of preeclampsia:current concepts. Am J Obstet Gynecol 179:1359-1375, 1998
PubMed
P.187 掲載の参考文献
1) Anderson S:Mechanisms of injury in progressive renal disease. Exp Nephrol 1:34-40, 1996
 
2) Remuzzi G, Bertani T:Pathophysiology and progressive nephropathies. N Engl J Med 339:1448-1456, 1998
PubMed
3) Kriz W, Norbert G, Lemley KV:Progression of glomerular diseases-Is the podocyte the culprit? Kidney Int 54:687-697, 1998
 
4) Anderson S, Brenner BM:Progressive renal disease:a disorder of adaptation. QJ Med 70:185-189, 1989
 
P.189 掲載の参考文献
1) 今井潤:家庭血圧と自由行動下血圧の基準値. 臨床高血圧 4:21-32, 1998
 
2) 今井潤, 阿部圭志:高血圧:診断と治療の進歩. 家庭血圧・24時間血圧の臨床評価. 日内会誌 84:47-52, 1995
 
3) Asmar R, Lacourciere Y:A new approach to assessing antihypertensive therapy:effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 18:1683-1690, 2000
 
4) Staessen JA, Thijs L, Fagard R et al:Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282:539-546, 1999
PubMed
5) Tsuji I Imai Y, Nagai K et al:Proposal of reference values for home blood pressure measurement:Prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens 10:409-418, 1997
PubMed
6) Ohkubo T, Imai Y, Tsuji I et al:Reference values for 24-hour ambulatory blood pressure monitoring based on aprognostic criteria:The Ohasama study. Hypertension 32:255-259, 1998
 
7) Kikuya M Hozawa A, Ohkubo T et al:Prognostic significance of blood pressure and heart rate variabilities. The Ohasama study. Hypertension 36:901-906, 2000
 
P.191 掲載の参考文献
1) Jansen RW, Lipsitz LA:Postprandial hypotension:epidemiology, pathophysiology, and clinical management. Ann Intern Med 122:286-295, 1995
PubMed
2) Shaw FE Kenny RA:The overlap between syncope and fals in the elderly. Posigrad Med J 73:635-639, 1997
 
P.193 掲載の参考文献
1) 木村玄次郎:腎と高血圧. 病態生理からのアプローチ, 東京医学社, 東京, 1998, pp.20-45
 
2) Sacks FM, Svetkey LP, Vollmer WM et al:Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 344:3-10, 2001
PubMed
3) Nagase M, Kato A, Ono T et al:Retrotransposons transcribed preferentially in proximal tubules of salt-hypertensive rats. Kidney lnt 55:905-1004, 1999
 
P.195 掲載の参考文献
1) Paradis P, Dali-Youcef N, Paradis FW et al:Over-expression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 97:931-936, 2000
 
2) Sivasubramanian N, Coker ML, Kurrelmeyer KM et al:Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104:826-831, 2001
PubMed
P.197 掲載の参考文献
1) 片山宗一:睡眠時無呼吸症候群と高血圧. 日本臨牀 58〔2000年増刊号, 高血圧 (下巻)〕:571-578, 2000
 
2) Nieto FJ, Young TB, Lind BK et al:Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. IAMA 283:1829-1836, 2000
 
3) Neubauer JA:Invited review:physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol 90:1593-1599, 2001
PubMed
4) 十川和博:低酸素応答におけるHIFの役割. 医学のあゆみ 194:752-756, 2000
 
P.199 掲載の参考文献
1) 安藤譲二:シェアストレスと内皮細胞, メディカルレビュー社, 大阪, 1996
 
2) Ando J, Kamiya A:Blood flow and vascular endothelial cell function. Front Med Biol Eng 5:245-264, 1993
PubMed
3) Davies PF:Flow-mediated endothelial mechanotransduction. Physion Rev 75:519-560, 1995
 
4) Ando J, Korenaga R, Kamiya A:Flow-induced endothelial gene regulation. In:Mechanical Forces and the Endothelium, ed. by Lelkes PI, Harwoood Academic Publishers, the Netherlands, 1999,p. 111-126
 
P.201 掲載の参考文献
1) Kuwajima I, Imai Y, Shimada K et al, group oboJ-Ms:Incidence of and factors contributing to morning hypertension:results of the Japanese Multicenter Study on Barnidipine with Ambulatory Blood Pressure Monitoring. Blood Pressure Monitoring 6:S31-S34, 2001
 
2) Gosse P, Ansoborlo P, Lemetayer P et al:Left ventricular mass is better correlated with arising blood pressure than with office or occasional blood pressure. Am J Hypertens 10:505-510, 1997
PubMed
3) Gosse P, Cipriano C, Bemurat L et al:Prognostic significance of blood pressure measured on rising. J Hum Hypertens 15:413-417, 2001
 
4) Panza JA, Epstein SE, Quyyumi AA:Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 325:986-990, 1991
PubMed
5) DeQuattro V, Lee DD, Allen J et al:Labetalol blunts morning Pressor surge in systolic hypertension. Hypertension 11:1198-1201, 1998
 
6) Pickering TG Levenstein M, Walmsley P:Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. Am J Hypertens 7:844-847, 1994
 
P.204 掲載の参考文献
1) 葛谷健, 中川昌一, 佐藤譲ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999
 
2) 寺内康夫, 戸辺一之, 門脇孝:遺伝因子と生活習慣一多因子遺伝を中心に. 日本内科学会雑誌89:1500-1506, 2000
 
3) Kadowaki T:Insights into insulin resistance and type 2 diabetes from knockout mouse models J Clin Invest 106:459-465, 2000
PubMed
P.207 掲載の参考文献
1) Kotchen JM, McKen HE, Kotchen TA:Blood pressure trends with aging. Hypertension 4 (suppl 3):S128-S134, 1982
 
2) Burke V, Beilin LJ, Dunbar D:Tracking of blood pressure in Australian children. J Hypertens 19:1185 1192, 2001
 
P.209 掲載の参考文献
1) Matsuzawa Y:Pathophysiology and molecular mechanisms of visceral fat syndrome:The Japanese experience. Diabetes Metab Rev 13:3-13, 1997
PubMed
2) Matsuzawa Y, Funahashi T, Nakamura T:Molecular mechanism of metabolic syndrome X:contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146-154, 1999
PubMed
3) Funahashi T, Nakamura T, Shimomura I et al:Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38:202-206, 1999
PubMed
P.211 掲載の参考文献
1) Barker DJP:The fetal origins of hypertension. J Hypertens 14 (suppl 5):S117-S120, 1996
 
2) Law CM, Shiell AW:Is blood pressure inversely related to birth weight? The strength of evidence from asystematic review of the literature. J Hypertens 14:935-941, 1996
 
3) 水嶋春朔, 杤久保修:出生時体重・体格と血圧:the Barker hypothesis. 日本臨牀[2000年増刊号高血圧(下巻)] 56:402-405, 2000
 
P.213 掲載の参考文献
1) Chrysant SG:Treatment of white coat hypertension. Curr Hypertens Rep 2:412-417, 2000
PubMed
2) Verdecchia P:Prognostic value of ambulatory blood pressure. Current evidence and clinical implications. Hypertension 35:844-851, 2000
PubMed
3) 加藤順子, 今井潤:白衣高血圧とは. 循環器科 40:99-105, 1996
 
P.215 掲載の参考文献
1) 秋口一郎:無症候性脳血管障害. 日本医事新報 3677:23-26, 1994
Medical*Online
2) 冨本秀和, 秋口一郎:びまん性白質病変. 変貌する脳卒中, 無症候性脳梗塞をめぐって, 尾前照雄, 亀山正邦監修, メディカルレビュー社, 大阪, 1998, pp.277-286
 
P.217 掲載の参考文献
1) Sutton-Tyrrell K Bostom A, Selhub J et al:High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96:1745-1749, 1997
PubMed
2) Welch GN, Loscalzo J:Homocysteine and atherosclerosis. N Engl J Med 338:1042-1050, 1998
 
3) Morita H, Kurihara H, Yoshida S et al:Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. Circulation 103:133-139, 2001
PubMed
4) Guttormsen AB, Ueland PM, Nesthus I et al:Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≧40u mol/liter). The Hordaland Homocysteine Study. J Clin lnvest 98:2174-2183, 1996
 
5) Boushey CJ, Beresford SA, Omenn GS et al:A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049-1057, 1995
PubMed
P.219 掲載の参考文献
1) Franklin SS, Khan SA, Wong ND et al:Is pulse pressure useful in predicting risk for coronaly heart disease?The Framingham heart study. Circulation 100:354-360, 1999
 
2) Tochikubo O, Kawano Y, Miyajima E et al:Circadian variation of hemodynamics and baroreflex functions in patients with essential hypertension. Hypertens Res 20:157-166, 1997
PubMed
3) Smulyan H, Safar ME:The diastolic blood pressure in systolic hypertension. Ann Inter Med 132:233-237, 2000
 
P.221 掲載の参考文献
1) 特集:無症候性脳血管障害. 日内会誌 86:423-827, 1997
 
2) 上村和夫:無症候性脳血管障害の診断基準-厚生省研究班報告. 無症候性脳血管病変, 端和夫, 小林祥泰編, 南山堂, 東京, 1999, pp.3-7
 
P.224 掲載の参考文献
1) Fukamizu A:Genomic expression systems on hierarchy and network leading to hypertension:long on history, short on facts. Hypertens Res 23:545-552, 2000
PubMed
2) Stec DE, Sigmund CD:Physiological insights from genetic manipulation of the renin-angiotensin system. News Physiol Sci 16:80-84, 2001
PubMed
P.227 掲載の参考文献
1) 0'Brien E, Sheridan J, O' Malley K et al:Dippers and non-dippers. Lancet 2:397, 1988
 
2) Verdecchia P, Porcellati C, Schillaci G et at:Ambulatory blood pressure. An independent predictor prognosis in essential hypertension. Hypertension 24:793-801, 1994
 
3) Kario K, Matsuo T, Kobayashi H et al:Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 27:130-135, 1996
PubMed
4) Kario K, Pickering TG, Matsuo T et al:Stroke prognosis and abnormal nocturnal blood pressure dipping in older hypertensives. Hypertension 38:852-857, 2001
PubMed
5) 苅尾七臣, 星出聡, 島田和幸:日本臨床生理学会雑誌 31:123-127, 2001
Medical*Online

第6章 治療/ 疫学

P.231 掲載の参考文献
1) 荻原俊男, 菊池健次郎, 猿田享男ほか編:AII受容体拮抗薬のすべて第2版, 先端医学社, 東京, 1997
 
P.233 掲載の参考文献
1) 土屋健三郎編:疫学入門, 医学書院, 東京, 1983, p.2
 
2) 鎌谷直之編:ポストゲノム時代の遺伝統計学, 羊土社, 東京, 2001
 
P.235 掲載の参考文献
1) Lodish H, Berk A, Zipulsky SL et al:Gene replacement and transgenic animals. In:Molecular Cell Biology 4th ed., 1999, pp.281-291
 
2) Igoucheva O, Yooon K:Improvement of RNA-DNA oligonucleotide design by using mamalian neclear extracts. Gene Therapy and Regulation 1:165-176, 2000
 
3) Yoshida M, Horinouchi S, Beppu T:Trichostatin A and trapoxin:novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17:423-430, 1995
PubMed
P.237 掲載の参考文献
1) Miyauchi T, Masaki T:Pathophysiology of endothelin in cardiovascular system. Annu Rev Physiol 61:391-415, 1999
PubMed
2) Krum H, Viskoper RJ, Lacourciere Y et al:The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338:784-790, 1998
PubMed
P.239 掲載の参考文献
1) Gray GA, Battistini B, Webb DJ:Endothelius arepotent vasoconstrictors, and much more besides. TIPS 21:38-40, 2000
 
2) Russel FD, Molenaar P:The human heart endothelin system:ET-1 synthesis, storage, release and effect. TIPS 21:353-359, 2000
 
3) Luscher TF, Barton M:Endothelins and endothelin receptor antagonists. Circulation 102:2434-2440, 2000
PubMed
4) Benigni A, Remuzzi G:Endothelin antagonists. Lancet 353:133-138, 1999
PubMed
P.241 掲載の参考文献
1) Takami S, Imai Y, Katsuya T et al:Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 13:121-127, 2000
PubMed
2) Matsubara M, Ohkubo T, Michimata M et al:Japanese individuals do not harbor the T594M mutation but do have the P592S mutation in the C-terminus of the beta-subunit of the epithelial sodium channel:the Ohasama study. Am J Hypertens 18:861-866, 2000
 
3) Matsubara M, Metoki H, Suzuki M et al:Genotype of the βENaC gene have little influence on blood pressure level in the Japanese population:the Ohasama study. Am J Hypertens 15:189-192, 2002
 
4) Matsubara M, Kikuya M, Ohkubo T et al:Aldosterone synthase gene (CYP11B2) C-344T polymorphism, ambulatory blood pressure, and nocturnal decline in blood pressure in the general Japanese population :The Ohasama study. J Hypertens 19:2179-2184, 2001
 
5) Matsubara M, Ohmori F, Fujita F et al:Haplotypes of aldosterone synthase (CYP11B2) gene in the general population of Japan:The Ohasama study. J CIin Hypertens 23:603-610,2001
 
6) Ishikawa K, Imai Y, Katsuya T et al:Human G-protein beta3 subunit variant is associated with serum potassium and total cholesterol levels but not with blood pressure. Am J Hypertens 13:140-145, 2000
 
P.243 掲載の参考文献
1) lnagaki N:Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart. J Biol Chem 270:5691-5694, 1995
 
2) Inagaki N:A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 16:1011-1017, 1996
PubMed
P.249 掲載の参考文献
1) 大塚邦明:時間医学 (chronome) とヤヌス (Janus) 医学, メディカルレビュー社, 大阪, 1998, p.213
 
2) Pickering TG Ad Hoc Panel:Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 9:1-11, 1996
 
3) Otsuka K, Cornelissen G, Halberg F:Predictive value of blood pressure dipping and swinging with regard to vascular disease risk. Clin Drug Invest 11:20-31, 1996
 
4) 大塚邦明, 大森啓義, 西村芳子ほか:血圧日内変動と心血管事故の発症予測-心拍変動減少と血圧変動増大. 自律神経 37:183-189, 2000
 
5) Witte K, Schnecko A, Buijs RM et al:Effects of SCN lesions on circadian blood pressure rhythm in normotensive and transgenic hypertensive rats. Chronobiol Int 15:135-145, 1998
PubMed
P.251 掲載の参考文献
1) 健康日本21:http://www.kenkounippon21.gr.jp/kenkounippon21/intro/index_menul.html
 
2) 上島弘嗣:日本の高血圧世界の高血圧 (2) 国民の血圧水準の低下と循環器疾患死亡率の減少. 血圧 1:194-201, 1994
 
P.253 掲載の参考文献
1) Pitt B, Zannad F, Remme WJ et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717, 1999
PubMed
2) Brilla CG:Aldosterone and myocardial fibrosis in heart failure. Herz 3:299-306, 2000
PubMed
3) McMahon EG:Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 1:190-196, 2001
PubMed
4) 高田佳史, 高沢謙二:抗アルドステロン療法の有効性. 別冊・医学のあゆみ循環器疾患-state of arts Ver. 2, 医歯薬出版, 東京, 2001, pp.340-342
 
P.255 掲載の参考文献
1) 勝谷友宏, 檜垣實男, 荻原俊男:高血圧症の病因遺伝子. 最新医学 55:2437-2442, 2000
Medical*Online
2) 勝谷友宏, 檜垣實男, 荻原俊男:本態性高血圧症の原因遺伝子解析. 日本臨牀 58[2000年増刊号高血圧(上巻)]:497-501, 2000
 
P.257 掲載の参考文献
1) Phillips IM:Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 29:177-187, 1997
 
2) Dzau VJ, Gibbons GH, Morishita R et al:New perspectives in hypertension research:potentials of vascular biology. Hypertension 23:1132-1140, 1994
PubMed
3) Morishita R Higaki J, Aoki M et al:Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method. In:Progression of Chronic Renal Diseases, ed. by Koide H, Contribution to Nephrology 118, 1996, pp.254-264
 
4) 青木元邦, 森下竜一, 荻原俊男:高血圧の遺伝子治療. 分子心血管病 2:205-212, 2001
Medical*Online
P.259 掲載の参考文献
1) MacMahon S, Peto R:BP, stroke, and coronary heart disease. Part 1, prolonged differences in BP:prospective observational studies corrected for the regression dilution bias. Lancet 335:765-774, 1990
 
2) Investigation of non response bias in NHANESII:Am J Epidemiology 117:507-515, 1983
 
3) Rowland M, Roberts J:Blood pressure levels and hypertension in persons ages 6-74 years. United States, 1976-80. In:NCHS Advance Data, No 84, Vital and Health Statistics of the National Center for Health Statistics, US Department of Health and Human Services, Washington DC, 1982, pp.1-11
 
4) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. Results in patients with diastolic BPs averaging 115 through 129 mmHg. JAMA 202:116-122, 1967
 
5) Veterans Administration Cooperative Study Group on Antihypertensive Agent:Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood perssure averaging 90 through 114 mmHg. JAMA 212:1143-1152, 1970
 
P.261 掲載の参考文献
1) Kitiyakara C, Wilcox CS:Antioxidants for hypertension. Curr Opin Nephrol Hypertens 7:531-538, 1998
PubMed
2) Ness AR, Chee D, Elliott P:Vitamin C and blood pressure-an overview. J Hum Hypertens 11:343-350, 1997
PubMed
3) Duffy SJ, Gokce N, Holbrook M et al:Treatment of hypertension with ascorbic acid. Lancet 354:2048-2049, 1999
PubMed
P.263 掲載の参考文献
1) 荻原俊男, 日和田邦男編:老年者高血圧の治療指針 (改訂版), 先端医学社, 東京, 1999
 
2) 日本高血圧学会高血圧治療ガイドライン作成委員会:日本高血圧治療ガイドライン2000年版, 日本高血圧学会, 東京, 2000, pp.5966
 
P.265 掲載の参考文献
1) Staessen JA, Gasowski J, Wang JG et al:Risks of untreated and treated isolated systolic hypertension in the elderly:meta-analysis of outcome trials. Lancet 355:865-872, 2000
PubMed
2) Gueyffier F, Bulpitt C, Boissel JP et al:Antihypertensive drugs in very old people:asubgroup meta-analysis of randomised controlled trials. Lancet 353:793-796, 1999
 
P.267 掲載の参考文献
1) The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
PubMed
2) 藤井潤, 芦田映直:降圧剤の選び方と使い方 第2版, 南江堂, 東京, 1996
 
3) 芦田映直:今日の高血圧診療, 中外医学社, 東京, 2000
 
P.269 掲載の参考文献
1) Guidelines Subcommittee:1999 World Health Organization-lnternational Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183, 1999
 
2) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch lntern Med 157:2413-2446, 1997
PubMed
3) 日和田邦男, 荻原俊男, 松本正幸ほか:老年者の高血圧治療ガイドライン-1999年改訂版-. 日老医誌 36:576-603, 1999
 
4) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン2000年版, 日本高血圧学会, 東京, 2000
 
5) 日本高血圧学会高血圧治療ガイドライン作成委員会編:実地医家のための高血圧治療ガイドライン, 日本高血圧学会, 東京, 2001
 
P.272 掲載の参考文献
1) Higaki J, Baba S, Katsuya T et al:Deletion allele of Angiotensin-converting enzyme gene increases riskof essential hypertension in Japanese men. The Suita study. Circutation 101:2060-2065, 2000
 
2) Mannami T, Katsuya T, Baba S et al:Low potentiality of Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism as a useful predictive marker for carotid atherogenesis in a large general population of a Japanese city. The Suita study. Stroke 32:1250-1256, 2001
 
3) Ishikawa K, Baba S, Katsuya T et al:T+31C polymorphism of Angiotensinogen gene and essential hypertension. Hypertension 37:281-285, 2001
PubMed
4) Iwai N, Katsuya T, Ishikawa K et al:Human prostacyclin synthase gene and hypertension. The Suita study. Circutation 100:2231-2236, 1999
PubMed
5) Iwai N, Baba S, Mannami T et al:Association of sodium channel γ-subunit promoter variant with blood pressure. Hypertension 38:86-89, 2001
 
6) Tsujita Y, Iwai N, Katsuya T et al:Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese:The Suita study. Hypertens Res 24:105-109, 2001
PubMed
7) Takagi S, Baba S, Iwai N et al:The Aldehyde dehydrogenase 2 gene is a risk factor fbr hypertension in Japanese but does not alter the sensitivity to pressor effects of alcohol:The Suita study. Hypertens Res 24:365-370, 2001
 
P.276 掲載の参考文献
1) American Diabetes Association:Treatment of hypertension in adults with diabetes. Diabetes Care 25:S71-S89, 2002
 
P.279 掲載の参考文献
1) Weber M:Emerging treatments for hypertension:potential role for vasopeptidase inhibition. Am J Hypertens 12 (11 Pt 2):139S-147S, 1999
 
2) 平田恭信:Neutral Endopeptidase Inhibitor. 血管 15:147-165, 1992
 
3) 平田恭信:ナトリウム利尿ペプチドファミリーの病態生理的役割. 循環器科 38:555-559, 1995
 
4) Burnett JC Jr:Vasopeptidase inhibition:a new concept in blood pressure management. J Hypertens 17 (suppl):S37-S43, 1999
 
P.281 掲載の参考文献
1) 清原裕:糖尿病と高血圧の疫学. 血圧 7:933-988, 2000
 
2) 谷崎弓裕, 清原裕, 藤島正敏:脳血管障害の危険因子と予防対策. 医学と薬学 39:213-220, 2001
 
3) Kiyohara Y, Kato I, Iwamoto H et al:The impact of alcohol and hypertension on stoke incidence in a general Japanese population:the Hisayama study. Stroke 26:368-372, 1995
 
P.283 掲載の参考文献
1) Guideline Committee:1999 World Health Organization-lnternational Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
 
2) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2000年版日本高血圧学会, 東京, 2000
 
P.285 掲載の参考文献
1) 大内尉義編:高齢女性の健康増進のためのホルモン補充療法ガイドライン, メディカルレビュー社, 大阪, 2001
 
2) Hulley S, Grady D, Bush T et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
PubMed
3) 大内尉義, 細井孝之:更年期障害. 岩波講座現 代医学の基礎12 老化と動脈硬化, 北徹, 藤原美定編, 岩波書店, 東京, 1999, pp. 181-201
 
P.287 掲載の参考文献
1) 日和田邦男:レニン阻害薬. 日本臨牀58[2000年増刊号. 高血圧 (下巻)]:263-268,2000
 
2) Simoneau B, Lavallee P, Anderson P et al:Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. Bioorg Med Chem 7:489-508, 1999
PubMed
3) Rahuel J, Rasetti V, Maibaum J et al:Structure-based drug design:the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 7:493-504, 2000
PubMed
4) Hollenberg NK:Pharmacologic interruption of the renin-angiotensin system and the kidney:differential responses to angiotensin-converting enzyme and renin inhibition. J Am Nephrol 10:S239-S242, 1999
PubMed
P.289 掲載の参考文献
1) 松岡博昭:大規模臨床介入試験メタアナリシス. 日本臨牀58(2000年増刊号. 高血圧 (下巻)):13-16, 2000
 
2) Pahor M, Psaty BM, Alderman MH et al:Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies:ameta-analysis of randomised controlled trials. Lancet 356:19491954, 2000
 
3) Neal B, MacMahon S, Chapman N:Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs:results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists:Collaboration. Lancet 356:1955-1964, 2000
PubMed
P.291 掲載の参考文献
1) Kannel WB:Fifty year of Framingham study contributions to understanding hypertension. J Hum hypertens 14:83-90, 2000
 
2) Kannel WB:The Framingham study;its 50-year legacy and future promise. J Atheroscler Throm 6:60-66, 2000
 
3) 築山久一郎, 大塚啓子:Framingham研究. 50年にわたる大規模調査成績からの理にかなった教訓. 薬理と治療 29 :493-510, 2001
 
P.293 掲載の参考文献
1) 厚生省公衆衛生局:昭和55年度循環器疾患基礎調査報告, 日本心臓財団, 東京, 1982
 
2) 厚生省保健医療局:第4次循環器疾患基礎調査 (平成2年) 報告, 循環器病研究振興財団, 東京, 1993
 
3) 循環器疾患基礎調査追跡調査委員会:脳卒中などによる寝たきり・死亡の健康危険度評価システム開発事業:「1980年循環器疾患基礎調査」追跡調査報告書, 日本循環器管理研究協議会, 東京, 1995
 
4) 上島弘嗣, 岡山明, 澤井廣量ほか:厚生省循環器疾患基礎調査の追跡調査の成果とその意義-NIPPON DATA80および90-. 厚生の指標 46:17-20, 1999
 
5) 「循環器疾患基礎調査成績に基づく医療のガイドライン作成事業」報告書, 日本循環器管理研究協議会, 東京, 1996
 
6) 上島弘嗣, 早川岳人, 喜多義邦ほか:わが国における高血圧の疫学:NIPPON DATA80. 血圧 7:421-426, 2000
 
7) 上島弘嗣, 早川岳人, 岡山明ほか:循環器疾患のコホート研究 NIPPON DATA:高齢者の循環器疾患による生活の質低下予防に関する研究. 循環器科 48:139-145, 2000
 
8) 上島弘嗣:「健康日本21」と自治体. 循環器疾患対策の展開. 公衆衛生 65:209-213, 2001
 
9) Hayakawa T, Okayama A, Ueshima H et al:Prevalence of Impaired Activities of Daily Living and the Impact of Stroke and Lower Limb Fracture in Elderly Persons in Japan. CVD Prevention 3:187-194, 2000
 
P.295 掲載の参考文献
1) 家森幸男, 水嶋春朔, 澤村誠ほか:高血圧, 主要循環器疾患の栄養因子-食事による予防のための国際比較研究. Deut Med Wochens (日本語版) 15:1825-1841, 1994
 
2) 家森幸男:第4章 現代の医食同源-生活習慣病を予防する食習慣. 講座人間と環境6 食の倫理を問う, からだと環境の調和, 安本教傳編, 昭和堂, 京都, 2000, pp.251-262
 
3) 家森幸男:世界の食環境の変容と沖縄の長寿. 健康の科学シリーズ 9:189-210,1999
 

書評

最近チェックした商品履歴

Loading...